Back to Search Start Over

Cellular delivery of relaxin-2 mRNA as a potential treatment for kidney fibrosis

Authors :
Chenguang Ding
Bo Wang
Xiang Feng Lai
Yingcong Guo
Greg Tesch
Xiaoming Ding
Jin Zheng
PuXun Tian
Sharon Ricardo
Hsin-Hui Shen
Wujun Xue
Source :
Materials Today Bio, Vol 21, Iss , Pp 100716- (2023)
Publication Year :
2023
Publisher :
Elsevier, 2023.

Abstract

Renal fibrosis is a pathological feature of chronic kidney disease and its progression correlates with kidney function impairment. Since there are currently no specific therapies for renal fibrosis, we explored whether inducing local production of the anti-fibrotic molecule relaxin-2 in kidney cells has potential as a strategy for suppressing the development of renal fibrosis. Our study examined whether delivery of relaxin-2 mRNA to kidney cells in vitro and in vivo could inhibit mechanisms leading to renal fibrosis. Transfecting relaxin-2 mRNA into cultured kidney cells inhibited fibrotic responses to TGF-β1 in an autocrine or paracrine manner by reducing fibrotic gene expression in kidney tubules, and reducing proliferation in kidney fibroblasts and mesangial cells. Similarly, cubosomes assisted delivery of relaxin-2 mRNA to mouse kidneys alleviated the fibrosis and inflammation associated with renal injury following unilateral ureter obstruction (UUO). Therefore, relaxin-2 mRNA exhibits potential as a novel therapy for inhibiting fibrosis and inflammation in chronic kidney disease.

Details

Language :
English
ISSN :
25900064
Volume :
21
Issue :
100716-
Database :
Directory of Open Access Journals
Journal :
Materials Today Bio
Publication Type :
Academic Journal
Accession number :
edsdoj.b7521d709d814e629a9bba5bbfe4f29b
Document Type :
article
Full Text :
https://doi.org/10.1016/j.mtbio.2023.100716